{"id":1211,"date":"2024-03-09T16:15:31","date_gmt":"2024-03-09T16:15:31","guid":{"rendered":"https:\/\/www.asklepios-advisors.com\/?p=1211"},"modified":"2024-03-11T12:06:15","modified_gmt":"2024-03-11T12:06:15","slug":"1med-acquires-french-clinical-research-company-evamed-accelerating-geographic-expansion","status":"publish","type":"post","link":"https:\/\/www.asklepios-advisors.com\/index.php\/2024\/03\/09\/1med-acquires-french-clinical-research-company-evamed-accelerating-geographic-expansion\/","title":{"rendered":"1MED Acquires French Clinical Research Evamed, Accelerating Geographic Expansion"},"content":{"rendered":"\n

London (UK), Agno (Switzerland) and Caen (France) – September 7th, 2023<\/em><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

1MED, a specialist Contract Research Organisation (\u201cCRO\u201d) providing regulatory and clinical support
to medical device companies, today announces that it has acquired Evamed, a CRO based in
northwest France also focused on the medical device market.
 
Created in 2005, Evamed has strong expertise in clinical study global management for all types of
medical device (from class I to class III) and for all therapeutic fields with most projects concentrated
on higher risk devices. Evamed helps manufacturers with complex studies to support efficient
regulatory approval and rapid access to market.
This acquisition establishes 1MED\u2019s presence in France, a key European market, and further
strengthens the company\u2019s capabilities in clinical trials, including further high complexity
interventional trials with higher risk devices.
Evamed\u2019s customers will benefit from having access to a larger platform and a wider network of
partners as well as 1MED\u2019s high quality specialist regulatory services. The acquisition is an important
step that reinforces 1MED\u2019s positioning as a pan-European boutique medical device CRO.
Enrico Perfler, Founder of 1MED commented: \u201cThis strategic move marks the beginning of a series of
M&A initiatives that will further strengthen our position in the market and enhance our capabilities.
With the addition of Evamed’s talented team of experts to the 1MED group, we are broadening our
range of services and expanding our geographical reach. Together, we will continue to transform the
complex landscape of medical device product approval, delivering reliable, streamlined, and high-
quality regulatory and clinical solutions to our clients\u201d.
Fabien Leclercq, founder of Evamed, added: \u201cBy joining 1MED, Evamed will be able to grant French as
well as international medtech companies access to a global network of clinical research expertise and
local workforce. It also strengthens our position as a medical device clinical studies specialist in
Europe.\u201d
Anne-Laure Meynier, Partner at Apposite said: \u201cWe are delighted 1MED completed its first
acquisition. We welcome Evamed as part of the 1MED group, thereby reinforcing the group\u2019s
presence on the French market, which is an important focus point, being a very dynamic market in
terms of medical devices and technologies developed there.\u201d
Asklepios Advisors introduced the deal to 1MED and Apposite Capital.
\u201cOur firm is delighted to have supported Apposite Capital in such transaction. This transaction
demonstrates Asklepios Advisors expertise in cross-border transactions\u201d Dr. Edouard Gobitz,
Managing Partner Asklepios Advisors.<\/p>\n","protected":false},"excerpt":{"rendered":"

London (UK), Agno (Switzerland) and Caen (France) – September 7th, 2023 1MED, a specialist Contract Research Organisation (\u201cCRO\u201d) providing regulatory and clinical supportto medical device companies, today announces that it has acquired Evamed, a CRO based innorthwest France also focused on the medical device market. Created in 2005, Evamed has strong expertise in clinical study global […]<\/p>\n","protected":false},"author":1,"featured_media":1212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/comments?post=1211"}],"version-history":[{"count":2,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1211\/revisions"}],"predecessor-version":[{"id":1357,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/posts\/1211\/revisions\/1357"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/media\/1212"}],"wp:attachment":[{"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/media?parent=1211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/categories?post=1211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.asklepios-advisors.com\/index.php\/wp-json\/wp\/v2\/tags?post=1211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}